TLX Telix Pharmaceuticals Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 2007191 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $803.79M | $516.55M |
| Cost of revenue | $377.36M | $180.39M |
| Gross profit | $426.44M | $336.16M |
| R&D expense | $171.25M | $127.93M |
| SG&A expense | $95.79M | $85.32M |
| Operating income | $29.78M | $55.18M |
| Interest expense | $181,000 | $64,000 |
| Pretax income | -$5.27M | $37.91M |
| Income tax | $1.86M | $4.23M |
| Net income | -$7.12M | $33.69M |
| EBITDA | $51.28M | $60.03M |
| EPS (basic) | -0.02 | 0.10 |
| EPS (diluted) | -0.02 | 0.10 |
| Weighted avg. shares (diluted) | 337.88M | 345.19M |
| Balance sheet | ||
| Cash & equivalents | $141.87M | $440.00M |
| Receivables | $129.20M | $86.93M |
| Inventory | $37.08M | $23.62M |
| Current assets | $330.28M | $570.12M |
| PP&E, netmay include right-of-use assets (IFRS) | $58.66M | $27.84M |
| Goodwill | $198.99M | $66.59M |
| Intangibles | $592.82M | $257.86M |
| Total assets | $1.16B | $940.38M |
| Current liabilities | $231.62M | $205.09M |
| Short-term debt | $13.11M | $11.76M |
| Long-term debt | $391.91M | $341.81M |
| Total debt | $405.02M | $353.57M |
| Total liabilities | $748.61M | $587.44M |
| Shareholders' equity | $415.38M | $352.94M |
| Net debt | $263.16M | -$86.42M |
| Cash flow statement | ||
| Operating cash flow | -$17.29M | $27.49M |
| Capital expenditure | $25.69M | $9.12M |
| Free cash flow | -$42.98M | $18.37M |
| Investing cash flow | -$285.92M | -$86.69M |
| Financing cash flow | -$3.72M | $416.79M |
| Depreciation & amortization | $21.51M | $4.85M |
| Stock-based compensation | $19.35M | $12.93M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.